Serum Galectin-3 as a Marker of Human Papillomavirus Infection

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

February 1, 2023

Conditions
Human Papillomavirus Infection
Interventions
PROCEDURE

cryotherapy

Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. Each wart was frozen using the spray technique by CRY-AC Liquid Nitrogen Dispenser Brymill, USA for 10 to 30 seconds until a 1- to 2-mm ice ball halo was formed surrounding the targeted area.

DIAGNOSTIC_TEST

serum Galectin-3 assay

From each patient and control, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe; the collected blood was placed on a plain tube without anticoagulant for 30 min at room temperature till coagulation occurs; after this, centrifugation of tubes was done for 20 min at 1000 rpm. The serum was separated into an aliquot and placed at -20 degrees Celsius for further analysis. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits supplied by ELK Biotechnology CO., LTD, Wuhan, China, catalog number (ELK2790) based on the Sandwich-ELISA technique as per the manufacturer's instructions.

Trial Locations (1)

71511

Assiut University, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT06005389 - Serum Galectin-3 as a Marker of Human Papillomavirus Infection | Biotech Hunter | Biotech Hunter